Global leaders have lauded India's leadership in scientific innovation and decisive action to combat the Covid-19 pandemic, as the country gets set to begin the world's largest vaccination drive against the novel coronavirus.
The Drug Controller General of India on Sunday approved the Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute and indigenously developed Covaxin of Bharat Biotech, for restricted emergency use in the country, paving the way for a massive inoculation drive.
All Indian vaccines being developed against the coronavirus will have to be stored at 2-8 degrees Celsius as the logistics have been worked out while considering temperature as a factor, Department of Biotechnology Secretary Renu Swarup said on Tuesday.
In a pandemic situation, restricted emergency use of vaccines is considered based on safety and immunogenicity data while phase three clinical trial is underway, Indian Council of Medical Research (ICMR) chief Balram Bhargava said on Tuesday.
Explaining the process followed in granting nod to Oxford Covid-19 vaccine and indigenously developed Covaxin, he said, "The existing pandemic situation, high mortality, available science and lack of definitive treatments were considered by the subject expert committee (SEC) on Covid-19 of CDSCO for granting accelerated approval to these vaccines, and that is in our legal provision."
More Chinese cities have begun mass Covid-19 vaccinations after the New Year holidays, days after China granted conditional approval for its domestically produced vaccine as the country prepares for the Spring Festival holiday next month.
Given the goal of vaccinating 50 million people ahead of the Spring Festival, which also marks the Chinese New Year holidays, a number of cities -- including Beijing, Shanghai, Shenzhen in South China's Guangdong Province, Luliang and Linyi -- have already started mass inoculations of the vaccine, covering nine key groups of people, the state-run Global Times reported on Tuesday